Global Karyotyping Market, By Product (Instruments, Software & Services, and Consumables & Accessories), Type (Spectral Karyotyping and Virtual Karyotyping), Application (Diagnosis, Personalized Medicines, Research, and Others), End User (Clinical & Research Laboratories, Hospitals, Pathology Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
Karyotyping Market Analysis and Size
Some primary factors expected to drive the market growth are the rising prevalence of genetic disorders, increasing cases of chromosomal abnormalities, and the adoption of sequencing testing. In addition, the broad product portfolio provided by market players and the rising application of karyotyping testing is another key driver expected to drive market growth. However, the high cost of karyotyping testing and cyber security concerns are expected to restrain market growth.
Furthermore, increasing technological advancements and innovation of new medical devices and instruments, rising healthcare expenditure on abnormal chromosomal diagnosis testing, and increasing research and development are expected to act as an opportunity for market growth. However, the lack of skilled professionals to perform genetic testing or karyotyping and stringent regulation policy are factors expected to challenge market growth.
Data Bridge Market Research analyzes that the global karyotyping market is expected to reach USD 494,982.13 thousand by 2030, at a CAGR of 5.9% during the forecast period 2023-2030. This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Product (Instruments, Software & Services, and Consumables & Accessories), Type (Spectral Karyotyping and Virtual Karyotyping), Application (Diagnosis, Personalized Medicines, Research, and Others), End User (Clinical & Research Laboratories, Hospitals, Pathology Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, Vietnam, New Zealand, Taiwan, Hong Kong, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Oman, Qatar, Bahrain, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Abbott, Applied Spectral Imaging, Empire Genomics, Inc., PerkinElmer Inc., Leica Biosystems Nussloch GmbH, MetaSystems., Sartorius AG, CytoTest Inc., SciGene Corporation, West Medica Produktions- und Handels- GmbH, MICROPTIC (A Hamilton Thorne Company), Laboratory Imaging s.r.o., Dewinter Optical Inc, BioDot, Stemmera Inc., Capricorn Scientific, and Creative Bioarray.
|
Market Definition
Karyotyping is a laboratory technique used to analyze and visualize the chromosomes of an individual or organism. It involves arranging and examining the chromosomes to identify structural or numerical abnormalities. This technique is commonly used in clinical genetics and cytogenetics to diagnose genetic disorders, determine chromosomal abnormalities, and study the genetic composition of cells. In addition to clinical applications, karyotyping is used in research to study chromosomal evolution, genetic diversity, and the relationships between species.
Global Karyotyping Market Dynamics
This section deals with understanding the market drivers, advantages, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Prevalence of Genetic Disorders
Genetic disorders occur when a mutation affects the genes or chromosomes with the wrong amount of genetic material. Genetic disorders may cause severe health problems, such as cancer, infertility in men or women, down syndrome, and Turner syndrome. The karyotyping testing can be performed on a sample of blood, bone marrow, amniotic fluid, or placental tissue. In karyotyping, changes in chromosome number associated with aneuploid conditions, such as trisomy 21 (Down syndrome), can be found. Duplications or inversions can be revealed by careful analysis of karyotypes' more subtle structural changes, such as chromosomal deletions and translocations.
Rising incidence rates of genetic disorders and high benefits, such as efficient and accurate detection, are some of the main factors that fuel demand for karyotyping tests that are expected to boost market growth.
- Increasing Cases of Chromosomal Abnormalities and Adoption of Sequencing Testing
Genomics-focused pharmacology is playing a greater role in treating various chronic diseases. Karyotyping to identifying chromosomal sequencing and patterns is evolving as a powerful tool for providing more precise findings. into molecular underpinnings to identifying the disease.
Karyotyping can be used to detect a variety of genetic disorders. For instance, a woman with premature ovarian failure may have a chromosomal defect that can be found by karyotyping. The test is also useful for identifying the Philadelphia chromosome, as a result of which chromosome can signal chronic myelogenous leukemia (CML).
Karyotypes can reveal changes in chromosome number associated with aneuploid conditions, such as trisomy 21 (Down syndrome). Careful analysis of karyotypes can also reveal more subtle structural changes, such as chromosomal deletions, duplications, translocations, or inversions.
Karyotyping reveals the size, shape, and number of chromosomes in a sample of cells. Clinical cytogeneticists analyze human karyotypes to detect gross genetic changes—anomalies involving several megabases or more of DNA. Thus, increasing adoption of genome-focused pharmacology for genetic disorders or chronic disease treatment is expected to drive the market growth.
Opportunity
- Increasing Technological Advancements and Innovation of New Medical Devices and Instruments
Advancements in sequencing technology have made it possible to undertake broad genetic testing on an individual patient basis within a clinically useful timeframe via exome and genome sequencing. Exome tests sequence the entire protein-coding region of the genome, demonstrating less than 2% of the genome. However, it contains approximately 85% of known disease-causing variants.
Various tools and devices are used to test various chromosomes more accurately and for efficient diagnosis. The earlier launched tools pose several challenges in diagnosis, for which market players are launching advanced diagnostic tools comprising new features. New technological advancements enhance the efficacy rate of the overall diagnostic process, boosting the manufacturer's credibility in the established market.
New and novel diagnostic tools launched earn the patient's beliefs and provide a new future that can positively affect market growth. Moreover, new product launches possess technological advancement, indicating that market players are constantly engaged in market growth. Technological advancement has enabled easy, accurate, and efficient chromosomal and genetic testing diagnosis. Thus, karyotype testing has the potential to get updated with time, hence creating opportunities for new and existing players to bring new products to the market. Hence, rising technological advancement and innovation of new medical devices and instruments are expected to act as an opportunity for market growth..
Restraint/ Challenge
- High Cost of Karyotyping Tetsing
Karyotyping testing is expensive, and some insurance companies may not cover it. The numerous genetic tests differ in costs per the targeted disease for which it is tested. The cost of karyotyping testing makes it unaffordable for healthcare providers and researchers in developing regions with limited healthcare budgets. This results in unequal access to advanced genetic testing, hindering the market's expansion in these areas. Academic and research institutions may have limited budgets for genetic research, and the high cost of karyotyping can restrict the number of studies that can be conducted. Researchers may opt for alternative, less expensive techniques, which can slow the adoption of karyotyping.
High testing costs can make karyotyping services unaffordable for many patients, limiting their access to these critical diagnostic tools. This is especially problematic in regions with limited healthcare resources and lower-income populations. Therefore, the high price of genetic and karyotyping testing is a major factor that can act as a restraint for the growth of the karyotyping market.There have been limited treatment options available for DMD, leaving patients and their families with few options to slow down the progression of the disease or improve their overall well-being.
Recent Developments
- In June 2023, Applied Spectral Imaging announced its collaboration with CytoCell division of OGT, a Sysmex Group company and a global leader in diagnostic genomic solutions. This partnership will expand its global reach and add value to customers in cytogenetics laboratories.
- In August 2022, Illumina, Inc. announced its investment in a new Shanghai-based facility. It allowed the company to serve its customers better and meet growing demand.
- In January 2022, Thermo Fisher Scientific, Inc. announced that it had completed its acquisition of PeproTech on December 30, 2021, for a total cash purchase price of approximately USD 1.85 billion. This helped the organization increase its product portfolio and generate revenue.
- In November 2021, Sartorius AG announced it would expand its operations in France and invest 100 million euros by 2025. This helped the organization increase its production capacity and overall revenue generation.
- In April 2021, MetaSystems announced that it had received the Grant of U.S. Patent for AI based Chromosome Analysis. This helped the organization in increasing its product portfolio.
Global Karyotyping Market Scope
The global karyotyping market is segmented into five notable segments based on product, type, application, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Instruements
- Software & Services
- Consumables & Accessories
On the basis of product, the market is segmented into instruments, software & services, and consumables & accessories.
Type
- Spectral Karyotyping
- Virtual Karyotyping
On the basis of type, the market is segmented into spectral karyotyping and virtual karyotyping..
Application
- Diagnosis
- Personalized Medicines
- Research
- Others
On the basis of application, the market is segmented into diagnosis, personalized medicines, research, and others.
End User
- Clinical & Research Laboratories
- Hospitals
- Pathology Laboratories
- Pharmaceutical & Biotechnology Companies
- Academic Research Institutes
- Others.
On the basis of end user, the market is segmented into clinical & research laboratories, hospitals, pathology laboratories, pharmaceutical & biotechnology companies, academic research institutes, and others.
Distribution Channel
- Direct Tender
- Reatil Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.
Global Karyotyping Market Regional Analysis/Insights
The global karyotyping market is analyzed and market size insights and trends are provided by country, product, type, application, end user, and distribution channel, as referenced above.
The countries covered in this global karyotyping market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, Vietnam, New Zealand, Taiwan, Hong Kong, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Oman, Qatar, Bahrain, and Rest of Middle East and Africa.
North America is expected to dominate the global karyotyping market due to increase prevalence of genetic disorder and rising healthcare expenditure.
Germany is expected to dominate in Europe due to increasing cases of chromosomal abnormalities and adoption of sequencing testing. China is expected to dominate Asia-Pacific is expcted to dominate the market as the strategic initiatives by the key market players are expanding significantly. South Africa is expected to dominate in Middle East and Africa due to increasing technological advancements and innovation of new medical devices and instrument.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Karyotyping Market Share Analysis
The global karyotyping market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the global karyotyping market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Abbott, Applied Spectral Imaging, Empire Genomics, Inc., PerkinElmer Inc., Leica Biosystems Nussloch GmbH, MetaSystems., Sartorius AG, CytoTest Inc., SciGene Corporation, West Medica Produktions- und Handels- GmbH, MICROPTIC (A Hamilton Thorne Company), Laboratory Imaging s.r.o., Dewinter Optical Inc, BioDot, Stemmera Inc., Capricorn Scientific, and Creative Bioarray, among others.
SKU-